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Abstract
Background: Several subunits of the SWI/SNF chromatin remodeling complex are implicated in both cancer and
neurodevelopmental disorders (NDD). Though there is no clinical evidence for an increased tumor risk in individuals
with NDDs due to germline mutations in most of these genes so far, this has been repeatedly proposed and
discussed. A young woman with NDD due to a de novo mutation in ARID1B now presented with a large renal (>
19 cm in diameter) and multiple hepatic angiomyolipomas (AMLs) but no other signs of tuberous sclerosis complex.
Methods: We analyzed tumor and healthy tissue samples with exome and panel sequencing.
Results: Additionally to the previously known, germline ARID1B variant we identified a post-zygotic truncating TSC2
variant in both renal and hepatic AMLs but not in any of the healthy tissues. We did not detect any further, obvious
tumor driver events. The identification of a passenger variant in SIPA1L3 in both AMLs points to a common clonal
origin. Metastasis of the renal AML into the liver is unlikely on the basis of discordant histopathological features.
Our findings therefore point to very low-grade mosaicism for the TSC2 variant, possibly in a yet unknown
mesenchymal precursor cell that expanded clonally during tumor development. A possible contribution of the
germline ARID1B variant to the tumorigenesis remains unclear but cannot be excluded given the absence of any
other evident tumor drivers in the AMLs.
Conclusion: This unique case highlights the blurred line between tumor genetics and post-zygotic events that can
complicate exact molecular diagnoses in patients with rare manifestations. It also demonstrates the relevance of
multiple disorders in a single individual, the challenges of detecting low-grade mosaicisms, and the importance of
proper diagnosis for treatment and surveillance.
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Background
ARID1B haploinsufficiency (OMIM #135900, *614556)
represents a frequent cause for neurodevelopmental disor-
ders (NDD) [1] comprising nonspecific intellectual disabil-
ity [2] or Coffin-Siris syndrome [3, 4]. The AT-rich
interactive domain-containing protein 1B encoded by the
ARID1B gene is a subunit of the SWI/SNF (SWItch/Su-
crose Non-Fermentable) chromatin remodeling complex.
This complex and many of its components play an
important role in a broad spectrum of neoplasms, acting
mainly as tumor suppressors [5]. ARID1B therefore
belongs to a growing number of genes in which germline
mutations cause NDDs while somatic mutations are
involved in cancer [6]. Though there is no clinical
evidence that individuals with NDDs due to germline mu-
tations in most of these genes and particularly in ARID1B
bear an increased risk for tumors [6, 7], this has been
repeatedly proposed and discussed [3, 8].
We report on a young woman previously diagnosed
with intellectual disability due to a de novo mutation in
ARID1B, in whom a huge renal and multiple hepatic
angiomyolipomas (AMLs) were diagnosed. Investigating
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their molecular cause revealed a post-zygotic stop-variant
in TSC2 in addition to the previously known germline
variant in ARID1B.
Methods
Clinical report
This individual had been reported previously (patient 5)
when the de novo variant c.3304C > T, p.(Arg1102*) in
ARID1B (NM_020732.3) was identified to be causative
for her intellectual disability [2]. Clinical details up to
12 years 8 months are described elsewhere [2]. At age 19
she had moderate cognitive impairment with good com-
prehension, speaking in two-word sentences and friendly
behavior. After indicating abdominal pain, examination
by ultrasound and computer tomography (CT) revealed
a large (diameter 19 cm) tumor in the left kidney and
multiple liver tumors (> 8, average diameter ca. 2 cm)
(Fig. 1a-c). Histological investigation after nephrectomy
and removal of one of the liver tumors confirmed them
to be AMLs (Fig. 1d-f ). Subsequent cranial MRI (mag-
netic resonance imaging), ultrasound of the right kidney
and detailed skin and nail examination did not reveal
any further clinical features of tuberous sclerosis com-
plex such as subependymal nodules or cortical dysplasia,
skin lesions or ungual fibromas. Apart from two single
seizures in early infancy she had no history of epilepsy.
Meanwhile, cardiologic evaluation and computer tomog-
raphy of the lung did not reveal further anomalies.
DNA extraction and sequencing
DNA from peripheral blood lymphocytes (PBL) was
extracted by standard procedures. DNA from cultured
fibroblasts (obtained from a cleft palate surgery speci-
men) and from renal tubular cells grown from a urine
specimen of the remaining healthy kidney as described
by others [9] were extracted using the Qiagen DNAeasy
system according to manufacturer’s recommendations
(Qiagen, Hilden, Germany).
Genomic DNA from marked tumor and neighboring
non-neoplastic tissues was extracted from 5 μm sections.
After de-paraffinization the NucleoSpin Tissue kit was
used according to the manufacturer’s protocol (Macher-
ey-Nagel, Düren, Germany), and subsequently lysis with
proteinase K at a concentration of 0.8–1.0 U per digest
Fig. 1 Renal and hepatic AMLs. a Abdominal CT scan showing the large AML of the left kidney. b CT of the liver showing three lesions indicated
by arrows. c Macroscopic picture of the renal AML. d Histopathology with haematoxylin and eosin (HE) staining showing blood vessels lacking
elastic tissue (“angio”), smooth muscle cells (“myo”) and adipose tissue (“lipoma”) close together as a typical sign of angiomyolipoma. e HE
staining of a region from the large kidney AML showing the ordinary smooth muscle differentiation and rhabdoid/epithelioid cell features. f HE
staining of a region from the resected hepatic AML, being composed mainly of fat cells
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at 55 °C overnight was performed. Exome sequencing of
DNA from blood, renal and liver tumor was performed
on an Illumina HiSeq 2500 system (Illumina, Inc., San
Diego, USA) after enrichment with the SureSelect Target
Enrichment v6 technology (Agilent Technologies, Santa
Clara, CA). Sequencing of DNA from unaffected renal
and hepatic tissues and from fibroblasts and renal tubular
cells was performed on an Illumina MiSeq system using
the TruSight Cancer panel. Complete coverage (>20x) for
TSC1 (NM_000368.3) and TSC2 (NM_000548.3) was en-
sured. MLPA analysis for TSC1 and TSC2 on PBL DNA
was performed using the kits P046 and P124 from
MRC-Holland (Amsterdam, The Netherlands). Variants in
TSC2 and SIPA1L3 (NM_015073.2) were validated by
Sanger sequencing using standard procedures.
Resulting sequencing reads were aligned and processed
as described previously [10]. Concurrent variant calling
of the two AML and the PBL exome BAM files together
with 13 control samples from the same machine run was
performed using freebayes version 1.1.0 [11]. SnpEff/
SnpSift version 4.3p [12] with dbNSFP [13] was used for
annotation. Potential somatic variants at coding and
splice region positions from the freebayes calls were
filtered to have an alternative allele fraction (AF) ≤1% in
blood and of ≥5% in the respective tumor. Only sites
with a read coverage of ≥10 in each sample and with ≥5
alternative allele reads in the tumor were considered.
Additionally, variants present with an allele depth of ≥2x
in 13 in-house controls from the same run were
excluded. Copy number variation (CNV) screening from
exome data was done with CNVkit version 0.9.4.dev0
[14]. BAM files were then visually inspected at regions
of interest using the IGV browser version 2.4.7 [15, 16].
Results
Analysing exome data from blood and renal and hepatic
AMLs showed the known variant in ARID1B, as ex-
pected, in about 50% of the reads, respectively (Fig. 2a
and Additional file 1: Figure S1). No further pathogenic
variant in ARID1B, nor loss of heterozygosity (LOH) was
observed in tumor tissues (Additional file 1: Figures S2
and S3). Analysis of TSC1 and TSC2 revealed the
Fig. 2 Molecular analyses on various tissues. a Overview of the analyzed tissue samples using exome, panel or Sanger sequencing and the results
for the respective genomic regions of interest. Both somatic variants in TSC2 and SIPA1LR were identified and confirmed. No evidence for
complete LOH at the ARID1B and TSC2 loci was found in the AML samples. Also see Additional file 1: Figures S1, S4 and S5 for details including
IGV snapshots and Sangers sequencing results. b Schematic 2 × 2 contingency table of the different possible hypotheses for the tumor formation
with arguments supporting each of the four combinations; the color intensity encodes perceived likeliness. VAF, variant allele frequency; CR, copy
ratio; *: this one read is likely an artefact, compare Additional file 1: Figure S5
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pathogenic variant c.3099C > G, p.(Tyr1033*) [17] in
TSC2 (NM_000548.4) in 67.3% (270/401) of the reads in
DNA from the renal and in 41.2% (49/119) of reads from
the hepatic AML, while it was not detected in any of the
179 reads from blood (Fig. 2a and Additional file 1: Fig-
ure S1). Panel sequencing on DNA from unaffected
renal and liver tissues and from fibroblasts did not
detect the TSC2 variant in any of the 31 to 508 reads,
respectively (Fig. 2a and Additional file 1: Figure S4), but
in one of 1210 reads in DNA from tubular cells. How-
ever, given its location at the beginning of the read and
as it occurred in only one read in an overlapping read
pair, it most likely represents an artefact (Fig. 2a and
Additional file 1: Figure S5).
Searching exome data for additional variants in renal
or hepatic AML and absent in blood revealed a variant
in SIPA1L3 (c.187_192dup, p.(Ala63_Thr64dup)
(NM_015073.2); COSM5959440), which was additionally
excluded by Sanger sequencing in DNA from fibroblasts
and healthy renal and hepatic tissues. Dysfunction of
SIPA1L3 has been discussed as a possible contributor to
the phenotype of some malignancies as it led to abnor-
malities of epithelial cell morphogenesis, cytoskeletal
structure and adhesion in a colorectal adenocarcinoma
cell line and as somatic SIPA1L3 alterations were found
in various, mainly epithelial cancer types [18, 19]. How-
ever, it has not yet been reported as a tumor driver (
[20] and Cosmic Cancer Gene Census (CGC)), and it
was not found to be mutated in a study searching for
additional somatic mutations in TSC-related lesions
[21]. Therefore, we consider this variant most likely a
passenger variant, though we cannot exclude a contrib-
uting effect in the tumor pathogenesis in our patient.
Copy number analysis from exome data indicated a pos-
sible deletion of TSC2 in a subpopulation of tumor cells.
However, analysis of heterozygous variant positions at
this locus did not show a significant deviation from 0.5,
therefore not supporting validity of this finding (Add-
itional file 1: Figures S2 and S3 and Additional file 2).
These analyses are challenged by variability in exome
data (e.g. coverage uniformity) and compromised tumor
purity. No other large regions of LOH or CNVs were
detected in the kidney or liver AMLs, indicating a
relatively stable constellation in both tumors (Additional
file 1: Figures S2 and S3; Additional file 2).
Discussion
Tuberous Sclerosis Complex (TSC; OMIM #191100,
*605284, #613254, *191092) is a multisystemic disorder
generally caused by germline variants in TSC1 or TSC2.
Multiple renal and extra-renal angiomyolipomas (AMLs)
represent one of the characteristic manifestations of
TSC. Renal AMLs are commonly observed in 80% of pa-
tients, while hepatic AMLs are less frequent and occur
in ca. 13% of affected individuals [22]. When renal and
hepatic AMLs were detected in the herewith reported
individual with ARID1B associated NDD and without
other frequent and typical signs of TSC, we considered
various possibilities: a) The AMLs might be causally
related to the germline ARID1B mutation. b) The AMLs
represent a mild and atypical manifestation of TSC in
the sentence of multiple diagnoses as reported recently
in a large study that revealed aberrations in two or more
disease loci in 4.9% of 7374 individuals with various
phenotypes tested by clinical exome sequencing [23]. Or
c) Another cause, un-related to the known ARID1B vari-
ant and not necessarily deducible from the AML pheno-
type might be responsible for the unusual presentation.
When performing exome sequencing on DNA from
the renal and hepatic AMLs, we found no indication for
a contribution of ARID1B or other commonly
cancer-related genes such as TP53 to their genesis.
While exome sequencing on blood did not detect a
variant in the TSC genes TSC1 or TSC2, we detected the
same pathogenic TSC2 variant in both renal and hepatic
tumor tissues. This and an additional variant in SIPA1L3
also exclusively found in both AMLs underline their
common clonal origin and open two possibilities: a) the
multiple hepatic AMLs being metastases from the huge
renal AML as rarely reported particularly for epithelioid
AMLs [24], or b) the AMLs resulting from a low-grade
mosaicism for the TSC2 variant. The first possibility
seems extremely unlikely based on the discordant histo-
pathological features of the AMLs. The huge renal
tumor was predominantly composed of epithelioid cells
entrapping only a very minor fatty component. In con-
trast, the resected hepatic AML was almost devoid of
such epithelioid cells and was composed almost exclu-
sively of fat cells closely mimicking a lipoma. Further
supporting the second possibility, mosaicism has been
frequently observed for TSC2 variants, including
low-grade mosaicism with allele frequencies < 1% or
variants only detected in skin tumor biopsies but not in
blood or saliva [25].
Of note, we did not reliably observe the TSC2 variant in
any of the sequencing reads from unaffected kidney, un-
affected liver, fibroblasts or renal tubular cells, which
might be expected in case of mosaicism. Given that the
lesional cell of these TSC-related mixed neoplasms, the
so-called “perivascular epithelioid cell” (PEC) has no
known physiological counterpart, renal and hepatic AMLs
might have their origin in a common, yet unknown mes-
enchymal precursor cell that expanded clonally during
tumor development [26]. This has previously been dis-
cussed for the co-occurrence of sporadic pulmonary lym-
phangioleiomatosis and renal AMLs with somatic TSC2
variants [27] and for TSC-associated AMLs [28]. Presence
of the TSC2 variant in only very few tumor precursor cells
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might therefore hinder detection in healthy tissues even
by next-generation-sequencing (overview in Fig. 2b).
In contrast to many other tumors, AMLs are genetically
relatively stable, and bi-allelic loss of TSC2 has been pos-
tulated as a sufficient and the main driver for AML devel-
opment [28]. Given the absence of a second TSC2 variant,
TSC2-LOH or any other evident tumor driver apart from
the unclear variant in SIPA1L3 in the renal and hepatic
AMLs of the herewith reported individual, a contribution
of the germline ARID1B variant to the tumorigenesis can-
not be excluded.
In any case, identifying the TSC2 variant in the herewith
reported individual has important consequences for her
medical care. It now prompts TSC specific surveillance
including regular echocardiograms, high-resolution com-
puted tomography of the lung and brain MRIs in addition
to regularly checks of the remaining kidney and the liver.
As mTOR inhibitors have been proven to be an efficient
therapy in TSC [29], this treatment option will be evaluated
and discussed based on her future disease course and
manifestations.
Despite a good sequencing depth of 179 reads the
TSC2 variant was not detectable in blood, meaning that
it also would not have been detected as an incidental
finding when performing exome sequencing because of
the NDD and thus would not have resulted in predictive
counseling and surveillance procedures. Proper medical
care in individuals with mental handicap is often chal-
lenging due to limited expression of medical discomfort
and thus missed co-morbidities or health complications
unrelated to the initial diagnosis.
Conclusion
Next to the value of combining genetic and pathologic
findings, this unique case demonstrates and emphasizes
several generally important aspects of genetic and medical
care such as a) considering multiple (independent) diag-
noses in a single individual, b) considering mosaicism or
post-zygotic variants and taking the efforts to detect them,
as c) a proper diagnosis might have important conse-
quences on treatment and surveillance. These efforts can
be challenged by potential mosaicism in multi-tumor syn-
dromes where the mutation-carrying cell of origin is still
unknown and might represent a very minor yet unidentifi-
able cell population leading to false-negative results.
Additional files
Additional file 1: Figure S1. IGV snapshots from exome sequencing.
Figure S2. Copy number analysis from exome data from the kidney AML
using CNVkit. Figure S3. Copy number analysis from exome data from
the liver AML using CNVkit. Figure S4. IGV snapshots from targeted
Cancer Panel and Sanger sequencing. Figure S5. IGV snapshot of the
artefact read identified in tubulus cells. (DOCX 1912 kb)
Additional file 2: Exome CNV calls and heterozygous SNPs in the
ARID1B or TSC2 region. Microsoft Excel spreadsheet file containing the
worksheets “summary”, “CNVkit_exome-aberrations” and
“LOH_ARID1BandTSC2”. The “summary” worksheet contains a detailed
description of all other worksheets and the respective data columns. The
“CNVkit_exome-aberrations” worksheet contains all the segments called
by CNVkit 0.9.4.dev0 which have a copy numer different from 2. The
“LOH_ARID1BandTSC2” worksheet contains all heterozygous single
nucleotide variants called in the PBL and both kindey and liver AML
samples with at least 20 bp coverage in each sample (to reduce sampling
bias) with 500 k bases of the ARID1B (chr6[hg19]:156599064–158,031,913)
or TSC2 (chr16[hg19]:1597990–2,638,713) gene. Fisher’s exact test from R
version 3.4.3 was used to calculate p-values between the PBL and AML
read coverages at each SNV position to check for significant deviation
from the expected allele fraction. (XLSX 48 kb)
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